Purpose The survival benefit from detecting additional breast cancers by preoperative magnetic resonance imaging (MRI) continues to be controversial. Methods We followed a cohort of 4454 women diagnosed with non-metastatic breast cancer (stage I-III) from 2/2005-6/2010 in five registries of the breast cancer surveillance consortium (BCSC). BCSC clinical and registry data were linked to Medicare claims and enrollment data. We estimated the cumulative probability of breast cancer-specific and all-cause mortality. We tested the association of preoperative MRI with all-cause mortality using a Cox proportional hazards model. Results 917 (20.6%) women underwent preoperative MRI. No significant difference in the cumulative probability of breast cancer-specific mortality was found. We observed no significant difference in the hazard of all-cause mortality during the follow-up period after adjusting for sociodemographic and clinical factors among women with MRI (HR 0.90; 95% CI 0.72-1.12) compared to those without MRI. Conclusion Our findings of no breast cancer-specific or all-cause mortality benefit supplement prior results that indicate a lack of improvement in surgical outcomes associated with use of preoperative MRI. In combination with other reports, the results of this analysis highlight the importance of exploring the benefit of preoperative MRI in patient-reported outcomes such as women's decision quality and confidence levels with decisions involving treatment choices.
Purpose
Over the past two decades , deaths from breast cancer have declined significantly, from 33 to 21 per 100,000 women annually [1] . Because randomized trials of breast conserving surgery (BCS) and mastectomy have demonstrated nearly equivalent mortality [2] [3] [4] [5] , critics of routine preoperative magnetic resonance imaging (MRI) assert that the additional cancers detected are either biologically inert or adequately treated with radiation [6, 7] . In addition, studies in recent years have provided evidence that preoperative MRI does not improve surgical margins or reoperation rates [8] and may increase the invasiveness of surgery from BCS to mastectomy or even bilateral mastectomy [9, 10] .
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Therefore, controversy exists over whether detecting additional cancers by breast MRI has yielded any benefit for survival or contributed to the decline in deaths from breast cancer.
The Early Breast Cancer Trialists' Collaborative Group [11] overview established that there is an important relationship between local control (stopping cancer at the site of origin) and survival in patients with breast cancer. However, there are little data available on the impact of preoperative breast MRI on recurrence rates. The only evidence available is from the short-term follow-up from the comparative effectiveness of MRI in breast cancer (COMICE) randomized controlled trial, which included assessment of local recurrence as a secondary endpoint [12] . Findings from the COMICE trial indicated that at 3 years, recurrence-free rates were similar with 94 and 96% for the breast MRI and no MRI groups [13] . Mortality outcomes from trials of preoperative MRI are not yet available.
In this study, we compared mortality outcomes for women with preoperative breast MRI and those without, specifically examining crude and adjusted mortality rates, and time to death between these two groups of women with a breast cancer diagnosis. We hypothesized that there would be no difference in mortality rates by receipt of breast MRI when adjusting for important confounders (Appendix A).
Methods

Data source
We conducted this study at six breast cancer surveillance consortium (BCSC) breast screening registries sponsored by the National Cancer Institute (BCSC; http://bcsc-resea rch. org/): in New Hampshire, New Mexico, North Carolina, San Francisco, Vermont, and Western Washington State (Kaiser Permanente Washington Registry), which send data to the Statistical Coordinating Center (SCC) for pooling and analysis [14] . The BCSC collects risk factor, clinical history, and sociodemographic data for women receiving breast imaging exams within the registries, which are further linked to both benign and malignant breast pathology outcomes, cancer registry data, and vital status.
For this study, we linked BCSC registries to Medicare claims data or electronic health records from 1998 to 2010 [15. ] Specifically, the Medicare MedPAR, Outpatient and Carrier files allowed us to capture all preoperative MRI to quantify comorbidities, and to determine women received breast conserving surgery or mastectomy (Appendix B). For women within the Kaiser Permanente Washington registry, electronic health records, rather than claims, were used to ascertain preoperative MRI.
Study population
BCSC women aged 66 and older with an initial non-metastatic breast cancer (stage I-III) diagnosed from February, 2005 through June, 2010 were included. We required women in this study to have received either breast conserving surgery (with or without radiation) or mastectomy within 6 months of their diagnosis. Women were required to have been enrolled in Medicare Parts A and B or Kaiser Permanente Washington continuously in the 12 months prior to diagnosis. Follow-up continued from time of breast cancer diagnosis through the end of 2014.
Outcome
Mortality was determined by a combination of BCSC vital status records obtained from state death tapes and Medicare records from 1998 to 2010 to determine date of death and only from BCSC records for 2011-2014. If BCSC and Medicare death dates differed by more than 30 days the earlier of the two death dates was chosen. Cases were excluded when a date of death was found in the BCSC before 2011 but not in Medicare. Time-to-death was defined as the interval between date of breast cancer diagnosis and date of death. Date of diagnosis was derived from BCSC pathology (breast biopsy) and cancer registry data. Deaths were considered breast cancer related if cause of death from state death tapes were coded as breast cancer. The maximum follow-up time was 8.3 years with median 4.6 years (IQR 3.2, 6.1).
Exposure
Our main exposure was receipt of preoperative breast MRI, defined as a breast MRI occurring 30 days prior to breast cancer diagnosis or within 6 months after diagnosis and prior to the initial breast cancer surgery. Codes used to identify breast MRI from MedPAR, Outpatient, and Carrier files are given in Appendix B.
Covariates
We included covariates that may be related to MRI receipt, which we hypothesized could confound the relationship between preoperative MRI and mortality. Covariates obtained from the BCSC database included age at diagnosis, race/ethnicity, educational attainment, first degree family history of breast cancer, breast cancer histology (in situ, invasive, ductal, lobular), breast density, comorbidities, and type of breast cancer surgery (BCS vs. mastectomy). Charlson comorbidity index score was based on data from the 12 months before diagnosis and was calculated using Medicare claims [16] .
Analyses
Women with and without preoperative MRI were characterized by sociodemographic, breast history, and breast cancer-related factors. Cell counts of < 11 were annotated and footnoted as required by our data use agreement with the Center for Medicare and Medicaid Services. We calculated raw all-cause mortality rates (per 1000 person-years) and 5-year cumulative probabilities of death by preoperative MRI and woman, tumor, and treatment characteristics. We plotted unadjusted cumulative probabilities for both breast cancer-specific mortality and other-cause mortality over time since diagnosis stratified by receipt of preoperative MRI. Using Cox proportional hazards models for time to all-cause mortality, we estimated the association between preoperative MRI and death, while adjusting for BCSC registry site, age, education, race/ethnicity, first degree family history of breast cancer, comorbidity, breast density, histology and breast cancer surgical treatment type. We did not estimate adjusted proportional hazards models for breast cancer-specific mortality due to the small number of events (n = 169).
For the multivariable analysis, we imputed unknown/ missing data (% missing) for the women's characteristics of race (12.8%), education (23.9%), breast density (19.8%), family history (8.4%) and histology (< 2%). We created five complete datasets using the multiple imputation by chained equations (MICE) algorithm [17] . To impute missing observations, MICE proceeds by estimating a regression model for each variable with missing data conditional on all other variables in the dataset. Multiple imputation preserves statistical efficiency by including all observations in the multivariable analysis while allowing for uncertainty in the imputed data by incorporating variability in results across imputations. Sensitivity analyses were conducted to evaluate the robustness of results across analyses with and without imputation. Analyses were performed in R version 3.4.0 with results reported as hazard ratios (HR) and 95% confidence intervals (CI). Imputation using MICE was carried out using the mice package in R [18] .
Results
Of the 4454 women meeting inclusion criteria, 917 (20.6%) underwent preoperative MRI. The majority of women with preoperative MRI was less than 75 years of age (69%), compared to 48% < 75 years among women without preoperative MRI. A greater proportion of women in the preoperative MRI group were white compared to the group without 44 ) per 1000 person-years for women without preoperative MRI. The unadjusted 5-year cumulative probability of death was 0.12 for women with MRI and 0.17 for those without. Crude all-cause mortality rates showed the expected increase with increasing age and were higher for women who were Black compared to White or Hispanic did not graduate from high school and had more comorbidities ( Table 2) .
In a multivariable Cox proportional hazard model, there was no significant difference in the hazard of all-cause mortality during the follow-up period comparing women with preoperative MRI to those without after adjusting for age, sociodemographic and clinical factors (HR 0.90; 95% CI 0.72-1.12) (Table 3) . Similarly, cumulative probability plots over time since diagnosis for other-cause mortality (Fig. 1a) and breast cancer-specific mortality (Fig. 1b) did not reveal significant differences between women with and without preoperative MRI, although cumulative probability plots of other-cause mortality suggested lower mortality among women with preoperative MRI (Fig. 1a) .
Sensitivity analyses yielded markedly similar results with and without missing observations included in the analysis (Data not shown). Models with and without multiple imputation resulted in similar point estimates for the hazard ratio and 95% CI for preoperative MRI, with the expected narrower confidence intervals with imputation (without imputation: HR 0.82; 95% CI 0.59-1.14).
Discussion
This study, based on a large, population-based observational cohort, supports the hypothesis that receipt of preoperative breast MRI is not associated with a significant difference in breast cancer-specific mortality, or all-cause mortality after adjusting for patient, cancer, and treatment characteristics. In crude analyses, mortality rates were significantly lower among women receiving preoperative MRI, but this difference did not persist after accounting for confounding factors such as age. Similarly, when examining the probability of mortality over time, breast cancer-specific mortality showed no differences by preoperative MRI status. These results indicate that preoperative MRI does not improve mortality overall or mortality due to breast cancer.
Controversy exists over whether detecting additional cancers by breast MRI yield any benefit for survival. Because randomized trials of breast conserving surgery and mastectomy have demonstrated nearly equivalent mortality [2] [3] [4] [5] , critics of routine preoperative MRI assert that the additional cancers detected are either biologically inert or adequately treated with radiation [6, 7] . Further, until recently, subsequent tumor events (second primaries and recurrences), which occur in 10-20% of women, were not thought to impact survival. However, recent published studies indicate that local recurrences have a negative impact on overall survival [2-5.] While breast MRI has been shown to be associated with excision of more tumor in initial treatment, a reasonable hypothesis is that breast MRI could decrease mortality via this early control. In a meta-analysis of preoperative MRI and 8-year local recurrence-and distant recurrence-free survival, the MRI and no MRI groups were not significantly different [19] . In theory, any causal effect of preoperative MRI on overall mortality should influence breast cancer-specific mortality but not mortality from other causes. Our findings from the cumulative probability analysis support a lack of effect of preoperative MRI influence on mortality. Even unadjusted cumulative probability of death was not significantly different for breast cancer-specific mortality, but plots for other-cause mortality suggested notably lower mortality among women with preoperative MRI. We would not expect MRI to affect mortality from other causes; thus our findings reinforce the lack of MRI effect on mortality. In fact, the difference in other-cause mortality appears similar or greater in magnitude to the effect on breast cancerspecific mortality, suggesting that this difference represents confounding. Together, these findings point to a putative effect of confounding among women with preoperative MRI (unadjusted analysis). Our findings suggest that both sociodemographic and clinical factors confound the relation between preoperative MRI and all-cause mortality, as predicted in our conceptual model (Appendix A). Specifically, older age, black race, more comorbidities, invasive histology, and mastectomy or breast conserving surgery without radiation, all were associated with both preoperative MRI and mortality. For observational studies, such as this one, inclusion of these hypothesized confounders is critical to evaluating the effectiveness of preoperative MRI in a valid manner. Currently, only observational data are available to assess preoperative MRI and mortality, although experimental evidence will be available in the future.
There are four randomized controlled trials of preoperative MRI, but to date, none have reported mortality outcomes [12, [20] [21] [22] . In fact, only the Alliance A11104 Clinical Trial from the American College of Radiology Imaging Network (ACRIN) has a primary endpoint possibly related to mortality, specifically local-regional recurrence rates at 5 years [22] . Small observational studies have reported the effect of preoperative MRI on disease-free survival. In a study of 174 women with early stage breast cancer with a median follow-up time of 8 years (range 0-13), no association of disease-free survival with preoperative MRI was found [23] . Because local recurrence risk and breast cancerspecific risk is low among women with early stage breast cancer, large observational studies are needed with adequate data to control for confounding and with sufficient longitudinal follow-up.
As in any observational study, confounding due to unobserved factors may occur, which in this study may reflect systematic differences between women who received preoperative MRI and those who did not. While we controlled for sociodemographic factors, comorbidities, cancer characteristics, and initial treatment, we were unable to account for subsequent treatment beyond initial therapy, comorbidity severity, or longitudinal patterns of care. We were able to account for registry-specific differences in practice patterns and/or population characteristics by accounting for potential correlation among/between observations. This study lends support to the growing consensus that preoperative breast MRI is not associated with a mortality benefit among women with breast cancer. If confirmed by the ongoing randomized control trials when sufficient follow-up has accrued, the role of preoperative breast MRI must be questioned. If it does not improve surgical outcomes or diminish breast cancer-specific mortality, its role may be more qualitative by providing information to women regarding the presence or absence of additional breast cancer following an initial diagnosis. Patient-centered outcomes may be important to examine regarding use of preoperative breast MRI, such as whether it improves decision quality related to surgical choices vis-a'-vis women's preferences and knowledge of outcomes associated with various surgical approaches [23, 24] . Although a modest increase in cost has been reported with preoperative MRI [25] , the tradeoffs of that cost with the potential for improved patient-centered outcomes should be explored.
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